课题基金 / 基金详情

TAMOXIFEN AND 9 CIS RETINOIC ACID IN ADVANCED BREAST CANCER

TAMOXIFEN AND 9 CIS RETINOIC ACID IN ADVANCED BREAST CANCER
他莫昔芬和 9 顺式维甲酸治疗晚期乳腺癌
批准号：
6276959
负责人：
CAROLYN WASSERHEIT
金额：
$2.03万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6276959
关键词：
breast neoplasms clinical research clinical trial phase I combination chemotherapy drug screening /evaluation female human subject human therapy evaluation neoplasm /cancer chemotherapy pharmacokinetics retinoate tamoxifen

项目摘要

项目成果

CAROLYN WASSERHEIT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This Phase I trial will attempt to determine the Maximally tolerated dose and pharmokinetics of a combination of standard dose tamoxifen with 9-cis retinoic acid. Dose-limiting toxicity, response rate, duration of response, and survival will be determined. Levels of the various subtypes of retinoic acid receptors, retinoid X receptor, and retinoid orphan receptor mRNA and protein in tissue derived from the patient's primary and metastatic tumors will be characterized.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DOXIL & TAXOTERE IN PATIENTS W/ ADVANCED MALIGNANCIES
TAMOXIFEN AND 9 CIS RETINOIC ACID IN ADVANCED BREAST CANCER
DOXIL & TAXOTERE IN PATIENTS W/ ADVANCED MALIGNANCIES
TAMOXIFEN AND 9 CIS RETINOIC ACID IN ADVANCED BREAST CANCER
海外基金